Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit.
Dr. Ure will review several experimental models demonstrating the reduction of liver fibrosis as CRV431’s most consistent effect.
“With no currently approved treatments for NASH, CRV431’s unique mechanism of action and broad range of effects during the progression from early- to late-stage disease provide for a very promising drug candidate,” CEO Dr. Robert Foster said in a statement.
“With pan-cyclophilin inhibition as its primary mode of action, CRV431 targets fibrosis, inflammation and cancer through multiple cyclophilin-mediated mechanisms. Our studies have demonstrated CRV431’s ability to reduce liver fibrosis in a number of models, as well as decrease tumor burden in advanced disease, suggesting applicability across various stages of liver disease,” he added.
